HRS-3095
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 08, 2026
A Trial of HRS-3095 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
July 08, 2026
A Trial of HRS-3095 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Atridia Pty Ltd.
New P1 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
June 13, 2026
HRS-3095-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes
(clinicaltrials.gov)
- P1 | N=82 | Completed | Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed
Trial completion • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
May 29, 2026
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
(clinicaltrials.gov)
- P2 | N=190 | Not yet recruiting | Sponsor: Chengdu Suncadia Medicine Co., Ltd.
New P2 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
December 04, 2025
HRS-3095-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes
(clinicaltrials.gov)
- P1 | N=66 | Recruiting | Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
1 to 5
Of
5
Go to page
1